{"entity":{"id":"nct07339176","kind":"trial","name":"Intratumoral N17350 in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of N17350 in melanoma, head and neck squamous cell carcinoma and non-small-cell lung cancer, run by Onchilles Pharma Inc, now recruiting.","summary":"Intratumoral N17350 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07339176 by Onchilles Pharma Inc, with 275 participants planned, started 2026-05-25 and due to reach its primary completion in 2028-07. Interventions recorded: N17350.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07339176","url":"https://clinicaltrials.gov/study/NCT07339176"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","head-and-neck","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07339176","phase":"1/2","setting":"A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors","sponsor":"Onchilles Pharma Inc","enrolled":275,"outcomes":[]},"route":"/trials/nct07339176/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}